Skip to main content
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in:

Open Access 22-04-2024 | Cytostatic Therapy | case report

Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor

Authors: Petar Popov, Oskar Steinbrecher, Anke Scharrer, Markus Raderer, Thomas Brodowicz, Matthias Preusser, Wolfgang Lamm, MD

Published in: memo - Magazine of European Medical Oncology | Issue 4/2024

Login to get access

Summary

SMARCA4-deficient undifferentiated tumor (SMARCA4-UTs) is an extremely rare and aggressive entity where no consensus on systemic treatment exists to date. We report the case of a 43-year-old woman with thoracic SMARCA4-UT who presented with rapid progression of disease after surgical resection and achieved complete radiologic remission under VDC-IE chemotherapy (vincristine, doxorubicin, and cyclophosphamide [VDC], alternating with ifosfamide and etoposide [IE]). The detailed case report is followed by a brief discussion and overview of current literature.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor
Authors
Petar Popov
Oskar Steinbrecher
Anke Scharrer
Markus Raderer
Thomas Brodowicz
Matthias Preusser
Wolfgang Lamm, MD
Publication date
22-04-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2024
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00973-x

Other articles of this Issue 4/2024

Treatment sequencing in gastroenteropancreatic neuroendocrine tumors

CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria

KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view

Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)

GATA2 deficiency: a mystery myelodysplasia

KRAS: Finally a druggable target in oncology?

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits